Ultrasound-enhanced rt-PA thrombolysis in an ex vivo porcine carotid artery model

Ultrasound Med Biol. 2011 Aug;37(8):1240-51. doi: 10.1016/j.ultrasmedbio.2011.05.011.

Abstract

Ultrasound is known to enhance recombinant tissue plasminogen activator (rt-PA) thrombolysis. In this study, occlusive porcine whole blood clots were placed in flowing plasma within living porcine carotid arteries. Ultrasonically induced stable cavitation was investigated as an adjuvant to rt-PA thrombolysis. Aged, retracted clots were exposed to plasma alone, plasma containing rt-PA (7.1 ± 3.8 μg/mL) or plasma with rt-PA and Definity® ultrasound contrast agent (0.79 ± 0.47 μL/mL) with and without 120-kHz continuous wave ultrasound at a peak-to-peak pressure amplitude of 0.44 MPa. An insonation scheme was formulated to promote and maximize stable cavitation activity by incorporating ultrasound quiescent periods that allowed for the inflow of Definity®-rich plasma. Cavitation was measured with a passive acoustic detector throughout thrombolytic treatment. Thrombolytic efficacy was measured by comparing clot mass before and after treatment. Average mass loss for clots exposed to rt-PA and Definity® without ultrasound (n = 7) was 34%, and with ultrasound (n = 6) was 83%, which constituted a significant difference (p < 0.0001). Without Definity® there was no thrombolytic enhancement by ultrasound exposure alone at this pressure amplitude (n = 5, p < 0.0001). In the low-oxygen environment of the ischemic artery, significant loss of endothelium occurred but no correlation was observed between arterial tissue damage and treatment type. Acoustic stable cavitation nucleated by an infusion of Definity® enhances rt-PA thrombolysis without apparent treatment-related damage in this ex vivo porcine carotid artery model.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Carotid Arteries*
  • Contrast Media / pharmacology*
  • Fibrinolytic Agents / pharmacology*
  • Fluorocarbons / pharmacology*
  • In Vitro Techniques
  • Recombinant Proteins / pharmacology*
  • Swine
  • Thrombolytic Therapy / methods*
  • Thrombosis / diagnostic imaging
  • Thrombosis / drug therapy*
  • Tissue Plasminogen Activator / pharmacology*
  • Ultrasonic Therapy / methods*
  • Ultrasonography

Substances

  • Contrast Media
  • Fibrinolytic Agents
  • Fluorocarbons
  • Recombinant Proteins
  • Tissue Plasminogen Activator
  • perflutren